Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sheppard Pratt Health System
Collaborators
NCT06085950 · Treatment Resistant Depression
NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression
NCT06938841 · Major Depressive Disorder, Treatment Resistant Depression
NCT06731621 · Treatment Resistant Depression, Autism Spectrum Disorder
NCT03537794 · Treatment Resistant Depression
Sheppard Pratt
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions